Assignee
MERRIMACK PHARMACEUTICALS INC
US·37 granted patents·81 pending applications·327 citations·filing 2002–2020
Top patents by PatentIndex Score
118 records- 0198US8992970B2Liposomes useful for drug deliveryMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Mar 31, 2015·39 cites·14 claims
- 0298US8703181B2Liposomes useful for drug deliveryMERRIMACK PHARMACEUTICALS INC·Filed 2012·Granted Apr 22, 2014·40 cites·17 claims
- 0398US7846440B2Antibodies against ErbB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2008·Granted Dec 7, 2010·92 cites·18 claims
- 0497US10087464B2Compositions and methods for delivering nucleic acid to a cellMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Oct 2, 2018·16 cites·6 claims
- 0596US9492442B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Nov 15, 2016·19 cites·30 claims
- 0695US9339497B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted May 17, 2016·17 cites·27 claims
- 0794US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0894US9364473B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Jun 14, 2016·12 cites·29 claims
- 0992US9511155B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Dec 6, 2016·10 cites·19 claims
- 1092US9452162B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Sep 27, 2016·12 cites·35 claims
- 1191US10570119B2Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)MERRIMACK PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·4 cites·15 claims
- 1291US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 1389US9226964B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·9 cites·37 claims
- 1485US9487588B2Antibodies against the ectodomain of ERBB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Nov 8, 2016·4 cites·4 claims
- 1584US9688761B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Jun 27, 2017·4 cites·24 claims
- 1682US9458245B2ANTI-C-MET tandem Fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·6 cites·3 claims
- 1782US9345766B2Combination therapies comprising anti-ERBB3 agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted May 24, 2016·2 cites·5 claims
- 1881US9518130B2Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancersMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Dec 13, 2016·4 cites·22 claims
- 1979US9556274B2Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 31, 2017·2 cites·10 claims
- 2077US6730492B2Cell-based screening methodsMERRIMACK PHARMACEUTICALS INC·Filed 2002·Granted May 4, 2004·4 cites·4 claims
- 2174US10273304B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Granted Apr 30, 2019·1 cites·36 claims
- 2273US9527914B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Dec 27, 2016·1 cites·6 claims
- 2372US9657108B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted May 23, 2017·1 cites·6 claims
- 2470US9226966B2Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·2 cites·10 claims
- 2570US7423024B2Recombinant human alpha-fetoprotein as an immunosuppressive agentMERRIMACK PHARMACEUTICALS INC·Filed 2004·Granted Sep 9, 2008·1 cites·8 claims
- 2670US2009053254A1Recombinant human alpha-fetoprotein as an immunosuppressive agentMERRIMACK PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2769US2010056761A1Antibodies against erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2869US2019292271A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2967US2014127136A1Liposomes useful for drug delivery to the brainMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3067US2016338956A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3167US2014127238A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3267US2016339014A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3366US2017049768A1Methods for treating pancreatic cancer using combination therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3466US2016067182A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3565US2016081928A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3665US2014234314A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3765US2016106672A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3864US7083938B2Cell-based screening methodsMERRIMACK PHARMACEUTICALS INC·Filed 2004·Granted Aug 1, 2006·0 cites·5 claims
- 3964US2017065578A1Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4064US2017253662A1Dosage and administration of anti-egfr therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4163US9920131B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Mar 20, 2018·0 cites·18 claims
- 4263US2017073427A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4362US2016228428A1Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4461US10072299B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Sep 11, 2018·0 cites·21 claims
- 4561US9938346B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Apr 10, 2018·0 cites·24 claims
- 4661US9902999B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 27, 2018·0 cites·21 claims
- 4761US9885087B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 6, 2018·0 cites·21 claims
- 4861US7208576B2Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2003·Granted Apr 24, 2007·4 cites·3 claims
- 4961US2014170668A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 5060US9968694B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·0 cites·20 claims
Showing the top 50 of 118 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →